Blue Health Intelligence’s Post

Title: Customizing an Evidence Generation Plan and HEOR Roadmap for Product Value Optimization In today's healthcare landscape, demonstrating a product's value is paramount for its successful adoption and utilization. Customizing an evidence-generation plan and Health Economics and Outcomes Research (HEOR) roadmap is crucial in determining, demonstrating, and optimizing its value in the market. This process begins with a thorough assessment of the product's therapeutic value proposition, target patient population, and competitive landscape. Designing a comprehensive evidence-generation plan involves a mix of clinical trials, observational studies, real-world evidence generation, and health economic modeling to capture the full spectrum of the product's value proposition. The HEOR roadmap translates clinical data into actionable insights, informing market access and reimbursement strategies. Disseminating research findings effectively through scientific publications and targeted initiatives is essential. This customization should be iterative, evolving over time to remain relevant and aligned with market demands. Overall, a strategic approach to evidence generation and HEOR ensures organizations can navigate market access challenges, communicate their product's value proposition effectively, and achieve success in the competitive healthcare landscape. Read the full article @ https://lnkd.in/eeQADsQA

Great sessions, networking and interactions at ISPOR 2024 day2#ISPOR 2024 US #mcs #maxisclinicalsciences #rwe #digitaltransformation My takeaways of the day #ISPOR • The focus on integrated universal framework for patient experience in HTA #Wholehealthvalueassessment • Integrate Real world evidence to open pathways for wider patient access • Exploring Advancement & future in HEOR & RWE research with GenAI • How technology & AI can enhance the next generation of observational research

HEOR in Clinical Development: Driving Better Outcomes Through Real World Evidence 🔬 💡Health Economics and Outcomes Research (HEOR) is transforming healthcare by integrating economic and clinical outcomes. Here’s how HEOR makes a difference: 🔍 What is HEOR? HEOR evaluates the value of healthcare interventions, analyzing their economic impact and clinical outcomes. 🧑🔬 Contributions to Research HEOR supports evidence-based decisions, guiding healthcare providers, policymakers, and payers to make cost-efficient treatment choices. 👩⚕️ Enhancing Patient Treatment HEOR identifies cost-effective treatments, improving patient outcomes and access to quality care by emphasizing real-world evidence. 🔬 Role of HEOR Researchers HEOR researchers analyze data, model healthcare costs, and assess patient outcomes to inform policy and healthcare strategies. 🤝 HEOR and Clinical Development HEOR is integral to clinical development. From early-stage trials to post-marketing studies, HEOR ensures that clinical innovations are not only medically effective but also economically viable. It bridges the gap between clinical efficacy and real-world application. To learn more, refer to this document. This document, written by me highlights HEOR in Clinical Development to drive better outcome through Real World Evidence #HEOR #HealthEconomics #ClinicalResearch #ClinicalDevelopment #RWE #DATA #Evidence #PatientCare

Curation of the week from Gilles Paubert, Global Head of Cegedim Health Data: "The utility of real-world evidence for multiple stakeholders in the biopharma and healthcare sectors only continues to increase. So it is no surprise that the Professional Society for Health Economics and Outcomes Research (ISPOR), in its 2024-2025 Top 10 HEOR Trends horizon-scanning report, has named RWE the #1 trend affecting healthcare decision-making. The report highlights the contributions of non-interventional RWE studies to complementing or augmenting RCTs and the unique benefits of RWE compared to RCTs. Those advantages include greater representation of diverse patient profiles, visibility into health outcomes in real-world settings, and faster generation of evidence about product safety and effectiveness. In regulatory scenarios, RWE also contributes to the totality of evidence supporting the approval of new products and indications. To learn more about what ISPOR members consider further topics of interest and why ISPOR views RWE as a strategic HEOR priority, check out this summary on the society’s website." #realworlddata; #rwd; #realworldevidence; #rwe

Legislation changes such as the IRA, aging populations and innovative medicines with uncertain long-term benefits continue to pressure the ecosystem to deliver healthcare in a more cost-efficient manner. Basing drug prices on demonstration of value is a concept that all stakeholders - including payers and pharma - agree on, as seen in repeated interviews and surveys. However, identifying the relevant outcomes, developing a platform to capture them prospectively (expensive, slow) or analyze them from retrospective data (dearth of fit-for-purpose options with necessary clinical depth), doing this in patient populations relevant to individual payers, and within timelines that fit into payers’ budget review cycles, remain key barriers. I look forward to speaking on how to enable widespread adoption of this concept in practice during my Keynote at the 6th MarketsandMarkets RWE and Life Sciences Analytics Conference next week.

Introducing the heart of market access at Albion Rye. With more than over 100 recommendations; they aid the crucial growth of your Market Access, HEOR & RWE departments globally. 

The hēRo3 Revolution: accelerating and empowering HEOR analytics with cutting-edge digital solutions >> https://lnkd.in/eFweXSPn With the rapid pace of breakthroughs in biopharma, the marketplace is becoming increasingly competitive. As a result, companies need to ensure that early pipeline asset planning is focused on “value-for-money” strategies. HEOR teams can now meaningfully contribute at the decision-making table by providing rapid turnaround of HEOR models and presenting critical insights that are intuitive and engaging in real-time.    In this interview, Chad Rose, General Manager – hēRo3, explains how >> https://lnkd.in/eFweXSPn #HEOR #MarketAccess  via hēRo3 - HEOR Modeling (Part of Fishawack Health)

A strong evidence strategy delivers HEOR findings and economic models that iteratively support impactful scientific communication and value messaging. We at Genesis Research Group help you ask the right questions for comprehensive, evidence-based strategy development, know the analogs and competition and policy/pricing considerations of your product via landscape assessments, and build economic models for rapid insights, to ultimately communicate value.     To innovate differently is to engage differently: Many HEOR clients choose to take advantage of the agility, breadth, and efficiency of our Flexible Integrated Team (FIT), which can pivot quickly to meet changing needs while retaining access to Genesis Research Group tech-enabled, HEOR, RWE, market access expertise, and technology platforms, such as RPR. RPR enables better HEOR decision-making, allowing clients to review individual aspects of value demonstration or even entire evidence-generation plans and benefit from actionable insights at any stage. #HEOR #RWE #MarketAccess

For a long time, health technology assessment (HTA) agencies have considered quality-adjusted life years (QALYs) to be the measure of choice for valuing health outcomes. QALYs enable assessment of both the quality and quantity of life, and are required for cost-utility analyses, where the cost per QALY of two or more treatments is compared. In our commentaries on ISPOR's top 10 HEOR trends for 2024–2025, Kaylie Metcalfe (Consultant – Health Economics) explores the value of QALYs, criticisms of this measure, and alternative ways of measuring value. Read more at https://lnkd.in/eV-zQbPA #value #QALYs #marketaccess #Pharma #Medtech #HTA #ISPOR #HEOR